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Abstract
Mouse models are a valuable tool for studying acute injury and chronic remodeling of the myocardium in vivo. With the advent of genetic
modifications to the whole organism or the myocardium and an array of biological and/or synthetic materials, there is great potential for any
combination of these to assuage the extent of acute ischemic injury and impede the onset of heart failure pursuant to myocardial remodeling.
Here we present the methods and materials used to reliably perform this microsurgery and the modifications involved for temporary (with
reperfusion) or permanent coronary artery occlusion studies as well as intramyocardial injections. The effects on the heart that can be seen
during the procedure and at the termination of the experiment in addition to histological evaluation will verify efficacy.
Briefly, surgical preparation involves anesthetizing the mice, removing the fur on the chest, and then disinfecting the surgical area. Intratracheal
intubation is achieved by transesophageal illumination using a fiber optic light. The tubing is then connected to a ventilator. An incision made on
the chest exposes the pectoral muscles which will be cut to view the ribs. For ischemia/reperfusion studies, a 1 cm piece of PE tubing placed
over the heart is used to tie the ligature to so that occlusion/reperfusion can be customized. For intramyocardial injections, a Hamilton syringe
with sterile 30gauge beveled needle is used. When the myocardial manipulations are complete, the rib cage, the pectoral muscles, and the skin
are closed sequentially. Line block analgesia is effected by 0.25% marcaine in sterile saline which is applied to muscle layer prior to closure
of the skin. The mice are given a subcutaneous injection of saline and placed in a warming chamber until they are sternally recumbent. They
are then returned to the vivarium and housed under standard conditions until the time of tissue collection. At the time of sacrifice, the mice are
anesthetized, the heart is arrested in diastole with KCl or BDM, rinsed with saline, and immersed in fixative. Subsequently, routine procedures for
processing, embedding, sectioning, and histological staining are performed.
Nonsurgical intubation of a mouse and the microsurgical manipulations described make this a technically challenging model to learn and achieve
reproducibility. These procedures, combined with the difficulty in performing consistent manipulations of the ligature for timed occlusion(s) and
reperfusion or intramyocardial injections, can also affect the survival rate so optimization and consistency are critical.
Video Link
The video component of this article can be found at http://www.jove.com/video/2581/
Protocol
1. Sterile surgical instruments (Table 1) and 3" cotton tipped applicators are placed on a sterile underpad. The bead sterilizer (Germinator 500)
is turned on.
2. Mice (age: > 6 weeks; wt: > 18g) are anesthetized with an i.p. injection of 20μl/g BW of tribromoethanol (250mg/kg; duration - approximately
40 minutes).
3. When the mice are unresponsive to toe-pinch, a sterile lubricant (Tears Renewed) is applied to the eyes to protect them from desiccation and
the left side of the chest is coated with depilatory (e.g. Nair) to remove fur from the skin.
4. The depilatory is washed away with warm running water and betadine/alcohol swabbing is used to disinfect the surgical area.
5. The mouse is placed on a warm deltaphase isothermal pad which is fixed to a plexiglass table. Each limb is immobilized using tape and a
thick thread is placed horizontally under the top teeth to hold the upper jaw in place.
6. The table is positioned vertically and a fiberoptic light is shone directly onto the neck region for transesophageal illumination. This requires
precise placement such that the opening of the throat is viewed as a well lit orifice, thus enabling the trachea to be visualized to facilitate
insertion of the PE tubing.
7. The tubing is then connected to the ventilator (connected to a 95% O2/5% CO2) to administer constant positive pressure ventilation (TOPO
ventilator; rate 125 breaths/min; peak inspiratory pressure 10-12 cmH2O; *note: settings vary with strain and gender 1-3). Once ventilation is
confirmed by synchronous chest movements, the connection is fixed to the pad with tape to avoid extubation during the surgery.
8. Using toothed forceps to pull skin up and away from the chest, a #10 sterile scalpel blade attached to a #3 scalpel handle is used to make a
1.5cm incision in the skin parallel to the sternum.
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9. Curved Vanna microscissors are used to cut the pectoralis muscles and make a small hole in the intercostal muscle.
10. Straight, blunt microscissors are used to cut through 3 ribs.
11. A 9mm pediatric ophthalmic speculum is used to retract the rib cage.
12. Using the curved forceps, pull the pericardium away from the heart and use the toothed forceps to gently tear it open.
13. Using the Castroviejo needle holder, a 6mm tapered point 3/8 needle threads the 8-0 polyethylene suture underneath the left anterior
descending coronary artery (along the long axis of the heart) perpendicular to it.
1. For a temporary ligature that can be removed for timed reperfusion, a sterile 0.5-1cm piece of PE90 is placed on the heart in parallel to
the coronary artery. The suture, which has first been looped under the coronary artery, is then tied to the tubing. At the time it is to be
released, the ligature is loosened. This can be repeated as desired and the time of occlusion/reocclusion can be modified 4. Depending
on the length of the protocol and the type of anesthesia used, supplementation may be necessary.
2. For a permanent occlusion, the ligature laced under the coronary artery is simply tied. Blanching and dyskinesia are apparent and the
long end of the suture is cut 5-10.
3. For intramyocardial injection(s), a sterile Hamilton syringe with a 30 gauge sterile beveled needle is introduced into the base of the
heart above the area of injury on the right side of the ligature. The needle is then advanced into the area of injury and withdrawn slightly
so that the bevel can be seen approximately at the border zone. Some of the solution in the syringe (2-3μl) is injected into the heart and
the needle is held in place. The syringe is withdrawn another 1-3mm and the rest of the solution is injected. The syringe is held in place
until the bleb that is formed by the solution dissipates. The needle is then removed. If there is any bleeding, a cotton-tipped applicator is
gently pressed onto the needle insertion site until the bleeding stops 5-7.
14. Once the myocardial manipulations are complete, the rib retractors are removed and the thoracic cavity is closed with 2-3 mattress sutures
using 6-0 surgipro suture.
15. Two-three mattress sutures are then made to close the pectoralis muscles, 1-3 drops of 0.25% marcaine 1:10 in sterile saline (0.1ml/25g
mouse) is applied to the muscle and then 2-3 mattress sutures are made to close the skin.
16. The mouse is removed from the ventilator. Once rhythmic, rapid, shallow breathing is verified, the mouse can be extubated.
17. 0.5ml warm sterile saline is injected into the dorsal subcutaneous space and the mouse is placed on a warming pad in a cage until it regains
mobility (1 hour minimum).
18. For survival experiments, mice are placed back into their cages and returned to the vivarium until the time of sacrifice. During first 2 days,
moistened food is placed on the cage floor to facilitate feeding (so they don't have to reach up which may cause pain) and buprenorphine
should be administered every 6-12hr. Post-operative care also includes daily monitoring for the first week to verify adequate mobility,
grooming, and eating habits.
19. The surgical instruments are wiped clean with ethanol and inserted into the bead sterilizer before the next surgery.
20. At the time of sacrifice, mice are anesthetized with sodium pentobarbital (65mg/ml; 55-65 mg/kg). When an adequate plane of anesthesia is
achieved, the thoracic cavity is opened.
21. While the heart is still beating, a syringe with a 23 gauge needle containing cold potassium chloride (KCl, 30mM) or 2,3-butanedione
monoxime (BDM; 10mM) is used to puncture the posterior basal region of the ventricle and the solution is slowly injected into the chamber
until the heart is arrested in diastole.
22. Once the heart is removed, a syringe containing PBS is used to retrogradely perfuse rinse the heart to remove any blood that remains. For
acute studies, at the end of the reperfusion period, the LAD is re-ligated at the original point of occlusion. A solution containing 1% Evan's
blue is injected into the aorta. Once the heart is extracted, it is cut transversely into 3 sections of equal thickness, incubated in 1% 2,3,5-
triphenyltetrazolium chloride, and imaged for morphometric analyses 11. For chronic studies, the heart is then immersed in fixative, then
processed and embedded according to routine procedures. Slides can then be stained histologically and imaged for morphometric analyses
(using Scion, NIH Image J, or Image Pro Plus) 9,10,12.
Representative Results:
When done correctly, the survival rates in mice (male: age 8-10 weeks, 22-28g; female: age 10-12 weeks, 20-26g) are: over 90% in acute
ischemia/reperfusion and ischemic preconditioning experiments, over 85% in permanent artery ligation studies, and approximately 80% for
intramyocardial injections. Since early injury is more readily visible by metabolic changes rather than structural, infarct size determination in
ischemia/reperfusion and ischemic preconditioning experiments is performed by infusing 1% Evan's blue dye into the aorta which will perfuse the
heart that is not supplied by the LAD (Figure 1A). Once the heart is removed and transversely cut in half, the tissue is incubated in 1% solution
of 2,3,5-triphenyltetrazolium chloride to measure infarct size (Figure 1B). The areas are measured using Scion or NIH imaging software which
can be calibrated using a micrometer imaged at the same magnification. These numbers are used to calculate area at risk/left ventricle and
infarct size/area at risk 11. Strain differences can result in variations in body weight and heart size and so care should be taken to normalize these
measures to heart weight, body weight, or tibia length for comparative purposes.
Permanent artery ligation results in gross structural changes such as necrosis, wall thinning, and chamber dilation. Comparison of the effects of
treatment and/or time on infarct size and necrosis relative to the left ventricle, chamber area, septal wall and left ventricular free wall thickness in
the permanent occlusion model (Figure 2A) can also be measured using Scion or NIH imaging software. Collagen staining with picrosirius red/
fast green (Figure 2B) can be used to measure insterstitial fibrosis which correlates to functional indices of wall stiffening8-10. The image in Figure
3 represents the distribution of 6ul solution (Evan's blue) injected into the border zone of the heart following permanent artery ligation. Notice that
it proceeds in the direction of the injury as well as toward the base and also transmurally.
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Figure 1. A. Evan's Blue injected into the aorta prior to excision. This image shows the perfused regions of the heart (stained) and the
occluded area (unstained). B. Evan's Blue and TTC staining following acute ischemia/reperfusion injury. This is a representative image (20x)
showing the blue dye distribution which stained the unoccluded regions as well as TTC staining of metabolically viable tissue (red). Necrotic
areas do not stain and so they remain pale (outlined).
 
Figure 2. A. Hematoxylin and eosin stain. This is a representative image (20x) of H&E staining of a mouse heart cut transversely through
the infarct region at 4 days post-MI (20x). The * denotes tissue necrosis, arrows point to granulation tissue, RV = right ventricle and LV = left
ventricle. B. Picrosirius red and fast green stain. This is a representative image (20x) of picrosirius red/fast green staining of a cross-section of
mouse heart at 4 weeks post-MI. The cytoplasm stains green and collagen fibers are red.
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Figure 3. Evan's Blue dye stain distribution following 6ul intramyocardial injection. This is a representative image showing the global and
transmural distribution of Evan's Blue dye throughout the heart following 6ul intramyocardial injection at the border zone immediately following
coronary artery ligation (12x).
Discussion
Coronary heart disease continues to be an epidemiologically and fiscally significant public health problem. Considerable basic research is still
needed to understand the mechanisms by which injury and remodeling proceed and how potential therapeutics may modulate these processes if
they are to be developed for clinical use. Rodents are most commonly used and the wide range of genetically modified mice available makes this
species a more attractive model.
Although there are differences between mice and other species, there are many advantages to a murine model. Use of a simple dissecting scope
or magnifying glass and well lit conditions enable the vasculature to readily be seen (for detailed gross anatomy of vasculature, see Salto-Tellez
et al., 200413). To reduce the risk of post-operative mortality, it is very important to avoid severing large vessels since the total blood volume of a
25g mouse is less than 2ml14. In the event that excessive bleeding occurs, gentle application of pressure or pinpoint cauterization can be used to
stop the bleeding.
This procedure can also be modified in a variety of ways. For example, mice can be anesthetized using isoflurane, ketamine/xylazine, or sodium
pentobarbital and appropriate selection is determined by the duration of the protocol15-18. The toe-pinch reflex is the most commonly used
index of the depth of anesthesia. Further, to improve the probability for long term survival, some investigators use antiarrhythmic drugs such
as lidocaine to reduce the incidence of lethal arrhythmias19,20 however, it must be taken into account that this has recently been shown to have
antiapoptotic properties in an acute model21. Also, to reduce post-operative pain, analgesics such as buprenorphine can be administered for
the first 48 hours after surgery3,16,17,22,23. To maintain body temperature during surgery (especially for longer protocols), a rectal probe in series
with a heating pad is often used in place of the isothermal pad. For ischemia/reperfusion and/or ischemic pre- or postconditioning: the duration
of the occlusion(s) and reperfusion(s) can be altered; for permanent occlusion, the size of the infarct may be modified by adjusting the location
of the ligature; and for intramyocardial injections (eg. cells, proteins), there can be 1-3 injection locations and the volume per injection can be up
to 15 μl24. If cells are being injected, the gauge of the needle used (usually 26-30)5,25,26 should be chosen based on the size of the cells so the
internal diameter of the needle is large enough to avoid sheering. To avoid confounds due to inflammatory processes triggered by the surgery,
some investigators have reported using a snare that is manipulated ex vivo to occlude and reperfuse the hearts in a closed chest mouse at any
point after the surgery27-29. More recently, Gao et al.30 have shown that temporary and permanent occlusion can be performed without the need
for ventilation and a few laboratories have begun to use ultrasound to perform closed-chest intramyocardial injections25,31.
Since the first study demonstrating feasibility of ligating the coronary artery in mice was published by Johns and Olson in 195432, many others
have adopted this model and modified it to study various aspects of myocardial injury and remodeling3,33-45. The nature of mice in terms of size,
reproductive capacity, and comparatively less expense for purchase and maintenance make this species an appealing tool for a broad range of
physiologic and pathophysiologic studies. As the miniaturization of technology for imaging in vivo advances46-49, as well as means to perform
and analyze large scale genomics and proteomics, drug screening, efficacy of cell-based and/or protein therapies as well as biomaterials50-64,
combined with the increasingly wide range of genetic manipulations afforded by ubiquitous or tissue specific transgenic or mutant/knockout mice,
the murine model of myocardial infarction will undoubtedly continue to be an invaluable tool in evaluating acute cardiac injury and long term
remodeling. Therefore, there is unquestionable value in being able to perform these experiments reliably and reproducibly.
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